The Aim 100 2015: 80-71

The Aim 100 2015: 80-71


Horizon Discovery (HZD) provides research tools and services to larger institutions or laboratories that develop treatments derived from the genetic roots of serious diseases. Since its arrival on Aim last year at 200p a share, it has built the business with the help of three acquisitions. The latest will see Horizon pay out £6m for Vienna-based biotech Haplogen Genomics – a deal analysts said “makes sense” given Horizon has sold the group’s inventory for the past year.

To continue reading, register today

to enjoy limited access to the following:

  • Daily trading news
  • Funds coverage
  • Features on big investment themes
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Related topics

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now